UpdatedJan2018

Meghna Jani

Country: United Kingdom Contact e-mail: meghna.jani@manchester.ac.uk Mains diplomas/countries:

• MD: (MBChB), UK • MRCP(UK) Royal College of Physicians (London) • MSc in Clinical Rheumatology (merit), UK • PhD: Immunogenicity in response to biologic agents

Awarded Dec 2015 Current positions and hospital/university:

• NIHR Academic Clinical Lecturer (Jan 2016-current); Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, University of Manchester

• Specialty Trainee in Rheumatology (North West England) • MRC Clinical Research Fellow in Clinical Pharmacology and Therapeutics

(2012-15); University of Manchester Position within EULAR/international experience:

• EMEUNET education group leader • Member of EULAR task force for Rheumatoid Arthritis Management with

synthetic and biological DMARDs 2016 • Co-opted member of the EULAR Standing Committee on Education and

Training (ESCET) • International experience: Reade Institute/Sanquin, Amsterdam (April

2015) Role as EMEUNET working group member:

• Education and social media subgroups- education SG lead (Nov 2016-current)

• Tasks involved: Co-founded EULAR/EMEUNET ambassador programme, dissemination of educational events via calendar, set up EMEUNET twitter, ARD social media editor (both with Elena Nikiphorou and Mary Canavan)

Areas of Research/Interest:

UpdatedJan2018

Pharmacoepidemiology (treatment safety and effectiveness), biologics, immunogenicity, opioids, rheumatoid arthritis, psoriatic arthritis Keywords: rheumatoid arthritis, psoriatic arthritis, biologics, outcomes research and adverse events Selected Publications:

• Jani, M., Nikiphorou, E., Croft, A., Bukhari, M. Building the future of rheumatology: the role of national and international networks. Rheumatology (Oxford) 2018; 57: 405-407 doi: 10.1093/rheumatology/kew509.

• Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford) 2018 Jan 8. doi: 10.1093/rheumatology/kex434. [Epub ahead of print]

• Jani M, Dixon WG. Are opioids just an American problem? BMJ Dec

6;359:j5514. doi: 10.1136/bmj.j5514

• Smolen J, Landewé R, Bijlsma J, Jani M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis.2017 Jun;76(6):960-977.

• Jani M, Dixon WG, Kersley-Fleet L et al. Drug-specific risk and characteristics of

lupus and vasculitis-like events in rheumatoid arthritis patients treated with TNFi: results from BSRBR-RA. RMD Open. 2017;3:e000314.

• Jani, M, Isaacs, J. D., Morgan, A. W., et al. High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis. 2016 May 31. pii: annrheumdis-2015-208849.

• Jani M, Chinoy H, Warren RB et al. Clinical utility of random anti-tumour necrosis

factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis Arthritis and Rheumatology. 2015 May;67(8):2011-9. doi: 10.1002/art.39169.

• Jani M, Massey J, Wedderburn LR, et al. Genotyping of immune-related genetic

variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. Ann Rheum Dis. 2014 Ann Rheum Dis. 2014 Sep;73(9):1750-2. doi: 10.1136/annrheumdis-2014-205440.

• Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nature Reviews Rheumatology. 2014 May;10(5):284-294. doi: 10.1038/nrrheum.2013.197. Epub 2013 Dec 24.